ASSESSING DRUG EXPOSURE IN RODENT TOXICITY STUDIES WITHOUT SATELLITE ANIMALS

被引:11
作者
NEDELMAN, JR
GIBIANSKY, E
TSE, FLS
BABIUK, C
机构
[1] Sandoz Research Institute, East Hanover, 07936, New Jersey
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1993年 / 21卷 / 03期
关键词
TOXICOLOGY; PHARMACOKINETICS; AUC; CXT;
D O I
10.1007/BF01059783
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Five major objectives for pharmacokinetic investigations in support of toxicity studies are identified as follows: Assess whether animals exhibited measurable blood concentrations in a dose-dependent manner; estimate average area under the concentration-time curve (AUC) and maximal concentration (C(max)) for each treatment group; elucidate general patterns in the concentration-time (CxT) profile, and summarize relationships between CxT and treatment group; determine CxT dependence on day into study; and judge interanimal variabilitly and identify any animals with unusual concentration response. Such objectives are generally addressed in rodent toxicity studies by including ''satellite'' animals in the study. Satellite animals are extra animals dosed as per protocol but not subjected to toxicological and pathological observations and tests. Instead, they are used exclusively for the evaluation of pharmacokinetic characteristics of the test compound. In this paper, methods are described for achieving the five listed pharmacokinetic objectives in rodent toxicity studies without the use of satellite animals. A rat toxicity study is presented as an example.
引用
收藏
页码:323 / 334
页数:12
相关论文
共 8 条
[1]  
ATKINSON AC, 1985, PLOTS TRANSFORMATION, P85
[2]   TESTING FOR THE EQUALITY OF AREA UNDER THE CURVES WHEN USING DESTRUCTIVE MEASUREMENT TECHNIQUES [J].
BAILER, AJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1988, 16 (03) :303-309
[3]   ESTIMATION OF POPULATION PHARMACOKINETIC PARAMETERS USING DESTRUCTIVELY OBTAINED EXPERIMENTAL-DATA - A SIMULATION STUDY OF THE ONE-COMPARTMENT OPEN MODEL [J].
LINDSTROM, FT ;
BIRKES, DS .
DRUG METABOLISM REVIEWS, 1984, 15 (1-2) :195-264
[5]   OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT [J].
PECK, CC ;
BARR, WH ;
BENET, LZ ;
COLLINS, J ;
DESJARDINS, RE ;
FURST, DE ;
HARTER, JG ;
LEVY, G ;
LUDDEN, T ;
RODMAN, JH ;
SANATHANAN, L ;
SCHENTAG, JJ ;
SHAH, VP ;
SHEINER, LB ;
SKELLY, JP ;
STANSKI, DR ;
TEMPLE, RJ ;
VISWANATHAN, CT ;
WEISSINGER, J ;
YACOBI, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :465-473
[6]  
SEBER GAF, 1989, NONLINEAR REGRESSION, P68
[7]  
STEINER EC, 1990, SIMUSOLV REFERENCE G, V1
[8]  
1992, SAS P229 SASSTAT CHA